Taiwan to invest $250 billion in US semiconductor manufacturing


The Trump administration signed a deal worth $250 billion with Taiwan, in a move designed to help the United States boost domestic semiconductor manufacturing. This deal was announced by the U.S. Department of Commerce on Thursday.

Under this deal, Taiwanese semiconductor and tech companies have agreed to make direct investments into the U.S. semiconductor industry. According to a press release, these investments will span across semiconductors, energy, and AI “production and innovation”. Currently, Taiwan produces more than half of the world’s semiconductors.

Taiwan will also supply an additional $250 billion in credit guarantees for additional investments from these semiconductors and tech enterprises, according to the commerce department. The timeline for the investments is unclear.

READ: Biden administration to intensify restrictions on China’s access to AI chips (January 14, 2025)

In return for the investment, the U.S. will invest in Taiwan’s semiconductor, defense, AI, telecommunications, and biotech industries. The amount for this investment was not specified.

This news comes the day after the Trump administration published a proclamation reiterating the country’s goal to bring more semiconductor manufacturing back to the United States.

“This dependence on foreign supply chains is a significant economic and national security risk,” the proclamation stated. “Given the foundational role that semiconductors play in the modern economy and national defense, a disruption of import-reliant supply chains could strain the United States’ industrial and military capabilities.”

The proclamation also announced 25% of tariffs on some advanced AI chips. It also stated that once trade talks with other countries–like this deal with Taiwan–are complete, there would be additional semiconductor tariffs.

In 2025, Trump has made semiconductor manufacturing a central focus of his economic agenda, aiming to reduce U.S. reliance on foreign chip production and bring manufacturing back to American soil.

His administration has proposed aggressive trade measures, including a potential 100% tariff on imported semiconductors. However, companies that commit to building manufacturing capacity in the U.S. could be exempt according to previous reports.

In March last year, Taiwan Semiconductor Manufacturing (TSMC) announced plans to invest $100 billion into bolstering chip manufacturing in the U.S.

READ: The perils of Trump’s proposed tariff trade war (February 6, 2025

Semiconductors are the foundational components of modern technology. They power computing systems in products ranging from smartphones and automobiles to telecommunications equipment and military weapons.

According to a press release from the U.S. Department of Commerce, the U.S. share of global wafer fabrication declined sharply from 37 percent in 1990 to less than 10 percent in 2024. Today, most semiconductors are fabricated in East Asia due to foreign industrial policies.

Free Training

Source link

US manufacturing output unexpectedly increases in December


WASHINGTON, Jan 16 (Reuters) – U.S. factory production unexpectedly increased in December amid a surge in primary metals output that offset a decline at ​motor vehicle assembly plants, but activity contracted in the fourth quarter against ‌the backdrop of challenges from import tariffs.

Manufacturing output rose 0.2% last month after an upwardly revised 0.3% ‌gain in November, the Federal Reserve said on Friday. Economists polled by Reuters had forecast production for the sector, which accounts for 10.1% of the economy, falling 0.2% after a previously reported unchanged reading in November.

Production at factories increased 2.0% on a year-over-year ⁠basis in December. But it ‌dropped at a 0.7% annualized rate in the fourth quarter after growing at a 2.8% pace in the third quarter. Manufacturing ‍has been hurt by President Donald Trump’s sweeping import duties, which he has ironically defended as needed to restore a long-declining domestic industrial base.

Though the levies have shored up industries like ​primary metals that faced stiff foreign competition, and an artificial intelligence investment ‌boom has supported certain segments, the rest of manufacturing has struggled, with the sector shedding 68,000 jobs in 2025.

Economists have long argued a manufacturing renaissance was impossible because of structural issues, including worker shortages. They expected some improvement this year as Trump’s tax cuts take effect.

Primary metals production jumped 2.4%. There were also sizeable increases ⁠in the output of electrical equipment, appliances and ​components as well as aerospace and miscellaneous transportation. ​But motor vehicle production dropped 1.1%, declining for a fourth straight month. Motor vehicle output fell

2.8% on a year-on-year basis in December.

Mining output ‍fell 0.7% after ⁠rebounding 1.7% in the prior month. Frigid temperatures boosted demand for heating, lifting utilities production 2.6%. Utilities output dropped 0.3% in November. Overall industrial production ⁠increased 0.4% after a similar gain in November. Industrial output rose 2.0% on a year-over-year basis in ‌December. It grew at a 0.7% rate in the fourth quarter.

(Reporting ‌by Lucia Mutikani; Editing by Andrea Ricci)

Free Training

Source link

MLQ.ai | AI for investors


AI

January 15, 2026 at 9:39 PM • by

The U.S. Department of Commerce announced a trade agreement on January 15, 2026, under which Taiwanese semiconductor and technology companies will invest at least $250 billion directly in the United States, with an additional $250 billion in credit guarantees to bolster American manufacturing in semiconductors, energy and AI[1][2][4]. The deal caps U.S. tariffs on Taiwanese imports at 15% and includes reciprocal U.S. investments in Taiwan’s key industries.

Investment Commitments and Tariff Adjustments

Taiwanese firms agreed to direct investments totaling at least $250 billion in U.S. facilities for semiconductors, energy and AI production. Taiwan will also offer $250 billion in credit guarantees to facilitate supply chain expansion[1][2]. The framework establishes U.S.-based industrial parks and sets U.S. tariffs on Taiwanese goods at a maximum of 15%, down from previous 20% reciprocal rates, with zero tariffs applied to select items including generic pharmaceuticals and aircraft components[1][2]. Future tariffs will exempt Taiwanese companies building U.S. production capacity, allowing duty-free imports linked to new domestic manufacturing[1].

Addressing U.S. Supply Chain Vulnerabilities

The agreement targets the decline in U.S. global semiconductor fabrication share, which fell from 37% in 1990 to under 10% in 2024 due to offshoring[1]. Only 10% of semiconductors are currently produced domestically, heightening dependence on foreign supply chains[summary]. U.S. officials described the deal as advancing ‘America First’ trade policies to restore manufacturing leadership[1]. Taiwan, which produces the majority of the world’s advanced chips, plays a central role through companies like TSMC[2].

Reciprocal U.S. Investments in Taiwan

In return, the U.S. will facilitate investments in Taiwan’s semiconductor, defense technology, AI, telecommunications and biotechnology sectors[4]. The deal follows months of negotiations and comes ahead of a Supreme Court decision on presidential tariff authority[2]. Commerce Secretary Howard Lutnick’s department emphasized semiconductors’ role in competing with China and driving innovation[2].

Semiconductor Supply Chain Restructuring

Semiconductor Supply Chain Restructuring

The agreement marks a structured shift from Taiwan’s dominant role in global chip production toward shared manufacturing capacity with the U.S. By tying tariff relief to domestic investments, it incentivizes Taiwanese firms to relocate fabrication facilities stateside, potentially reducing geopolitical risks from Taiwan Strait tensions[1][2]. This addresses the stark imbalance where U.S. production has dwindled to under 10% of global output, making supply chains vulnerable to disruptions[1]. The $500 billion total commitment—split between direct investments and guarantees—provides concrete financing mechanisms absent in prior pacts like the CHIPS Act, which focused on subsidies rather than bilateral trade leverage[2].

Tariff caps at 15% with exemptions create a predictable environment for cross-border operations, favoring compliant investors over pure imports. This model could serve as a template for U.S. deals with other allies, balancing protectionism with alliance-building amid rising tensions with China, which relies heavily on Taiwanese chips[2].

U.S. Manufacturing Capacity Expansion Timeline

U.S. Manufacturing Capacity Expansion Timeline

Implementation will likely prioritize establishment of U.S.-based industrial parks, with initial Taiwanese investments targeting advanced node fabs for AI and defense applications over the next 2-3 years[1]. TSMC and other firms may accelerate existing Arizona and other U.S. projects, scaling to meet the $250 billion pledge through phased commitments tied to tariff benefits[2]. Credit guarantees could unlock private financing, speeding construction amid labor and material shortages.

Longer-term, reciprocal investments may enhance Taiwan’s defense tech resilience, potentially integrating U.S. firms into joint AI and biotech ventures by 2028[4]. Market reactions will hinge on Supreme Court tariff rulings, but early signals suggest reduced trade friction and bolstered U.S. competitiveness against China[2]. Monitoring company-specific announcements will clarify allocation across energy, AI and semis.

Free Training

Source link

Trump Administration Slaps 25% Tariffs on High-End NVIDIA and AMD AI Chips to Force US Manufacturing


In a move that marks the most aggressive shift in global technology trade policy in decades, President Trump signed a national security proclamation yesterday, January 14, 2026, imposing a 25% tariff on the world’s most advanced artificial intelligence semiconductors. The order specifically targets NVIDIA (NASDAQ: NVDA) and AMD (NASDAQ: AMD), hitting their flagship H200 and Instinct MI325X chips. This “Silicon Surcharge” is designed to act as a financial hammer, forcing these semiconductor giants to move their highly sensitive advanced packaging and fabrication processes from Taiwan to the United States.

The immediate significance of this order cannot be overstated. By targeting the H200 and MI325X—the literal engines of the generative AI revolution—the administration is signaling that “AI Sovereignty” now takes precedence over corporate margins. While the administration has framed the move as a necessary step to mitigate the national security risks of offshore fabrication, the tech industry is bracing for a massive recalibration of supply chains. Analysts suggest that the tariffs could add as much as $12,000 to the cost of a single high-end AI GPU, fundamentally altering the economics of data center builds and AI model training overnight.

The Technical Battleground: H200, MI325X, and the Packaging Bottleneck

The specific targeting of NVIDIA’s H200 and AMD’s MI325X is a calculated strike at the “gold standard” of AI hardware. The NVIDIA H200, built on the Hopper architecture, features 141GB of HBM3e memory and is the primary workhorse for large language model (LLM) inference. Its rival, the AMD Instinct MI325X, boasts an even larger 256GB of usable HBM3e memory, making it a critical asset for researchers handling massive datasets. Until now, both chips have relied almost exclusively on Taiwan Semiconductor Manufacturing Company (NYSE: TSM) for fabrication using 4nm and 5nm process nodes, and perhaps more importantly, for “CoWoS” (Chip-on-Wafer-on-Substrate) advanced packaging.

This order differs from previous trade restrictions by moving away from the “blanket bans” of the early 2020s toward a “revenue-capture” model. By allowing the sale of these chips but taxing them at 25%, the administration is effectively creating a state-sanctioned toll road for advanced silicon. Initial reactions from the AI research community have been a mixture of shock and pragmatism. While some researchers at labs like OpenAI and Anthropic worry about the rising cost of compute, others acknowledge that the policy provides a clearer, albeit more expensive, path to acquiring hardware that was previously caught in a web of export-control uncertainty.

Winners, Losers, and the “China Pivot”

The implications for industry titans are profound. NVIDIA (NASDAQ: NVDA) and AMD (NASDAQ: AMD) now face a complex choice: pass the 25% tariff costs onto customers or accelerate their multi-billion dollar transitions to domestic facilities. Intel (NASDAQ: INTC) stands to benefit significantly from this shift; as the primary domestic alternative with established fabrication and growing packaging capabilities in Ohio and Arizona, Intel may see a surge in interest for its Gaudi-line of accelerators if it can close the performance gap with NVIDIA.

For cloud giants like Amazon (NASDAQ: AMZN), Google (NASDAQ: GOOGL), and Microsoft (NASDAQ: MSFT), the tariffs represent a massive increase in capital expenditure for their international data centers. However, a crucial “Domestic Exemption” in the order ensures that chips imported specifically for use in U.S.-based data centers may be eligible for rebates, further incentivizing the concentration of AI power within American borders. Perhaps the most controversial aspect of the order is the “China Pivot”—a policy reversal that allows NVIDIA and AMD to sell H200-class chips to Chinese firms, provided the 25% tariff is paid directly to the U.S. Treasury and domestic U.S. demand is fully satisfied first.

A New Era of Geopolitical AI Fragmentation

This development fits into a broader trend of “technological decoupling” and the rise of a two-tier global AI market. By leveraging tariffs, the U.S. is effectively subsidizing its own domestic manufacturing through the fees collected from international sales. This marks a departure from the “CHIPS Act” era of direct subsidies, moving instead toward a more protectionist stance where access to the American AI ecosystem is the ultimate leverage. The 25% tariff essentially creates a “Trusted Tier” of hardware for the U.S. and its allies, and a “Taxed Tier” for the rest of the world.

Comparisons are already being drawn to the 1980s semiconductor wars with Japan, but the stakes today are vastly higher. Critics argue that these tariffs could slow the global pace of AI innovation by making the necessary hardware prohibitively expensive for startups in Europe and the Global South. Furthermore, there are concerns that this move could provoke retaliatory measures from China, such as restricting the export of rare earth elements or the HBM (High Bandwidth Memory) components produced by firms like SK Hynix that are essential for these very chips.

The Road to Reshoring: What Comes Next?

In the near term, the industry is looking toward the completion of advanced packaging facilities on U.S. soil. Amkor Technology (NASDAQ: AMKR) and TSMC (NYSE: TSM) are both racing to finish high-end packaging plants in Arizona by late 2026. Once these facilities are operational, NVIDIA and AMD will likely be able to bypass the 25% tariff by certifying their chips as “U.S. Manufactured,” a transition the administration hopes will create thousands of high-tech jobs and secure the AI supply chain against a potential conflict in the Taiwan Strait.

Experts predict that we will see a surge in “AI hardware arbitrage,” where secondary markets attempt to shuffle chips between jurisdictions to avoid the Silicon Surcharge. In response, the U.S. Department of Commerce is expected to roll out a “Silicon Passport” system—a blockchain-based tracking mechanism to ensure every H200 and MI325X chip can be traced from the fab to the server rack. The next six months will be a period of intense lobbying and strategic realignment as tech companies seek to define what exactly constitutes “U.S. Manufacturing” under the new rules.

Summary and Final Assessment

The Trump Administration’s 25% tariff on NVIDIA and AMD chips represents a watershed moment in the history of the digital age. By weaponizing the supply chain of the most advanced silicon on earth, the U.S. is attempting to forcefully repatriate an industry that has been offshore for decades. The key takeaways are clear: the cost of global AI compute is going up, the “China Ban” is being replaced by a “China Tax,” and the pressure on semiconductor companies to build domestic capacity has reached a fever pitch.

In the long term, this move may be remembered as the birth of true “Sovereign AI,” where a nation’s power is measured not just by its algorithms, but by the physical silicon it can forge within its own borders. Watch for the upcoming quarterly earnings calls from NVIDIA and AMD in the weeks ahead; their guidance on “tariff-adjusted pricing” will provide the first real data on how the market intends to absorb this seismic policy shift.

This content is intended for informational purposes only and represents analysis of current AI developments.

TokenRing AI delivers enterprise-grade solutions for multi-agent AI workflow orchestration, AI-powered development tools, and seamless remote collaboration platforms.
For more information, visit https://www.tokenring.ai/.



Free Training

Source link

BD announces $110m U.S. manufacturing investment


BD (Becton, Dickinson and Company), a leading global medical technology company, has announced a $110m investment to expand its production of prefillable syringes, helping accelerate biologic and GLP-1 drug delivery and supporting pharmaceutical reshoring in the U.S.

This investment will bring BD Neopak™ Glass Prefillable Syringe production to Columbus, Nebraska, creating approximately 120 new jobs and reinforcing the company’s supply resilience within its Pharmaceutical Systems portfolio.

“This is good news for Nebraska,” said Sen. Ricketts. “It has the potential to bring over 100 new jobs to our state. This investment further underscores BD’s ongoing commitment to keep critical manufacturing in states like Nebraska. I appreciate BD’s long-standing partnership with the Cornhusker State.”

The BD Neopak™ Glass Prefillable Syringe platform is purpose-built to meet the complex and evolving needs of biologics and combination products development. Available in 1 mL and 2.25 mL formats, the BD Neopak™ Glass Prefillable Syringe supports a wide range of formulation requirements, including high viscosity, drug-container compatibility, and integration with delivery devices. It is designed for seamless integration with autoinjectors, enabling flexible, patient-centric drug delivery in both clinical and at-home settings.

“As demand for biologics and GLP-1s accelerates, BD is strengthening its American manufacturing footprint to support U.S.-based drug delivery innovation and supply chain resiliency,” said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. “This investment in Nebraska, advances our long-term growth strategy and reflects our commitment to partnering with biopharmaceutical innovators as they bring advanced therapies to patients who require next-generation drug delivery solutions.”

Strategic Investments in Columbus, Nebraska

BD is investing $100m to establish BD Neopak™ Glass Prefillable Syringe production at its Columbus site, with supply expected to begin in mid-2026. This investment will also support additional line upgrades and capacity improvements across the site, ensuring BD can meet growing global demand for advanced injectable solutions. In addition, BD is investing $10m to enhance cannula manufacturing capabilities at the site, and together these investments will add approximately 120 new jobs.

This announcement builds on BD’s recent investment of more than $35m to expand prefilled flush syringe manufacturing in Columbus, which will add approximately 50 new jobs and strengthen the supply of critical medical devices to health care providers across the U.S. BD Columbus has been a strategic site within BD’s global manufacturing network for more than 75 years and is home to part of the company’s vertically integrated cannula manufacturing operations, including design and production. As the largest medical device manufacturer in the United States, these investments are part of BD’s commitment to invest more than $2.5bn in U.S. manufacturing capabilities over the next five years.

Strengthening U.S. Supply Chain Resilience

This expansion underscores the company’s commitment to building a more resilient and responsive pharmaceutical supply chain in the United States. By localizing production of the BD Neopak™ Glass Prefillable Syringe platform, BD is helping to ensure continuity, scalability, and speed to market for life-changing injectable therapies – especially as demand rises for biologics and combination products used to treat chronic and high-burden diseases.

As the global leader in biologics drug delivery, BD continues to invest in innovation and infrastructure to meet current needs and ensure that patients everywhere can benefit from the therapies of tomorrow.

Free Training

Source link

KULR Technology Group Awarded 5-year Preferred Battery Supply Agreement from Caban Energy; Expands U.S. Manufacturing Footprint


HOUSTON, Jan. 14, 2026 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), an energy-systems platform company that enables the safe, certifiable deployment of ultra-high-power lithium battery systems for space and defense programs, hyperscale AI data centers, and telecom infrastructure OEMs, today announced it was awarded a five‑year preferred battery supply agreement from Caban Energy (“Caban”), a Miami-based renewable energy services and technology company delivering flexible solutions for critical infrastructure. The agreement, generating an estimated $30 million in total revenue to KULR starting 2026, further reinforces KULR’s strategy to deliver mission‑critical energy‑storage technologies across digital infrastructure, communications, aerospace, and defense markets, while expanding U.S.‑based manufacturing capacity to support growing customer demand.

No Image

KULR’s expansion into lithium-based battery solutions for digital infrastructure and telecommunications underscores the increasingly central role of advanced energy storage in ensuring continuous, mission-critical network operations. In telecom environments, batteries serve as the primary line of defense against grid interruptions – preserving network availability, minimizing service outages, and sustaining communications during emergency conditions as expectations for uptime and resilience continue to rise. By integrating telecom-focused battery solutions into its portfolio, KULR is aligning its technology platform with the evolving requirements of digital infrastructure operators who require reliable, high-performance backup power to support 5G rollouts and long-term network scalability.

As part of the agreement, the Company took over Caban’s Plano, Texas‑based manufacturing assets, strengthening KULR’s domestic production footprint and accelerating its expansion into communications, fiber, and data‑center energy‑storage markets across the United States.

Get the latest news


delivered to your inbox

Sign up for The Manila Times newsletters

By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

“This supplier award and the addition of manufacturing assets are timely and important steps as we continue to scale into fast‑growing global markets,” said Michael Mo, Chief Executive Officer of KULR Technology Group. “By centralizing and integrating these capabilities into our U.S. manufacturing operations, we expect to increase development and production throughput and deliver high‑reliability energy systems at the scale required by our customers.”

Caban focuses on decarbonizing energy for critical infrastructure, including telecommunications networks and other mission‑critical facilities. A core component of Caban’s commercial model is Energy‑as‑a‑Service (EaaS), through which the company installs, operates, and owns renewable energy infrastructure while customers pay a predictable monthly fee without upfront capital expenditure. Caban’s EaaS offerings are designed to lower operating costs, reduce carbon footprint, eliminate risk exposure, and improve the reliability and predictability of energy supply. The company has experienced strong momentum in recent years, forging key partnerships and securing long-term contracts with some of the largest telecommunications companies in the world, including a new project with Digicel announced earlier this year. Its solutions have been successfully deployed across 12 countries, enabling businesses to enhance their energy resilience while meeting ambitious sustainability goals.

About KULR Technology Group, Inc.

KULR Technology Group, Inc. (NYSE American: KULR) is an energy-management and reliability platform company delivering certifiable battery safety, vibration-mitigation, and thermal control solutions that enable ultra-high-power lithium-ion systems and sensitive electronics to operate reliably across space and defense missions, hyperscale AI data centers, telecom infrastructure and mobility applications.

About Caban

Caban, founded in 2018, set out to tackle the challenge of decarbonizing one of the most fossil fuel-dependent industries. Initially focused on providing alternative energy solutions for the telecommunications industry in the Americas, the company has demonstrated success in supplying energy to several of the world’s largest telecom operators. Building on this momentum, Caban has scaled globally and expanded its reach to support clean energy needs across critical infrastructure sectors worldwide. Caban uniquely combines service, hardware, software, and finance tools to deliver reliable, clean power and boosts your bottom line. This turnkey approach allows clients to work directly with one trusted partner to achieve reliability and decarbonization across their operations.

For more information, visit www.cabanenergy.com.

Find KULR: Website | X | Telegram | LinkedIn | Instagram | TikTok | Facebook

Safe Harbor Statement

This release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our Form 10-K filed with the Securities and Exchange Commission on March 31, 2025, as may be amended or supplemented by other reports we file with the Securities and Exchange Commission from time to time. Forward-looking statements include statements regarding our expectations, beliefs, intentions, or strategies regarding the future and can be identified by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” and “would” or similar words. All forecasts are provided by management in this release are based on information available at this time and management expects that internal projections and expectations may change over time. In addition, the forecasts are entirely based on management’s best estimate of our future financial performance given our current contracts, current backlog of opportunities and conversations with new and existing customers about our products and services. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise.

Investor Relations:

KULR Technology Group, Inc.

Phone: 858-866-8478 x 847

Email: [email protected]

KULR Media Relations:

M Group Strategic Communications (on behalf of KULR)

Email: [email protected]

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/0b2da4ec-b5ec-46a6-8af2-19f9fac9a770

Free Training

Source link

KULR Technology Group Awarded 5-year Preferred Battery Supply Agreement from Caban Energy; Expands U.S. Manufacturing Footprint


HOUSTON, Jan. 14, 2026 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), an energy-systems platform company that enables the safe, certifiable deployment of ultra-high-power lithium battery systems for space and defense programs, hyperscale AI data centers, and telecom infrastructure OEMs, today announced it was awarded a five‑year preferred battery supply agreement from Caban Energy (“Caban”), a Miami-based renewable energy services and technology company delivering flexible solutions for critical infrastructure. The agreement, generating an estimated $30 million in total revenue to KULR starting 2026, further reinforces KULR’s strategy to deliver mission‑critical energy‑storage technologies across digital infrastructure, communications, aerospace, and defense markets, while expanding U.S.‑based manufacturing capacity to support growing customer demand.

KULR Caban Lockout

KULR’s expansion into lithium-based battery solutions for digital infrastructure and telecommunications underscores the increasingly central role of advanced energy storage in ensuring continuous, mission-critical network operations. In telecom environments, batteries serve as the primary line of defense against grid interruptions – preserving network availability, minimizing service outages, and sustaining communications during emergency conditions as expectations for uptime and resilience continue to rise. By integrating telecom-focused battery solutions into its portfolio, KULR is aligning its technology platform with the evolving requirements of digital infrastructure operators who require reliable, high-performance backup power to support 5G rollouts and long-term network scalability.

As part of the agreement, the Company took over Caban’s Plano, Texas‑based manufacturing assets, strengthening KULR’s domestic production footprint and accelerating its expansion into communications, fiber, and data‑center energy‑storage markets across the United States.

“This supplier award and the addition of manufacturing assets are timely and important steps as we continue to scale into fast‑growing global markets,” said Michael Mo, Chief Executive Officer of KULR Technology Group. “By centralizing and integrating these capabilities into our U.S. manufacturing operations, we expect to increase development and production throughput and deliver high‑reliability energy systems at the scale required by our customers.”

Caban focuses on decarbonizing energy for critical infrastructure, including telecommunications networks and other mission‑critical facilities. A core component of Caban’s commercial model is Energy‑as‑a‑Service (EaaS), through which the company installs, operates, and owns renewable energy infrastructure while customers pay a predictable monthly fee without upfront capital expenditure. Caban’s EaaS offerings are designed to lower operating costs, reduce carbon footprint, eliminate risk exposure, and improve the reliability and predictability of energy supply. The company has experienced strong momentum in recent years, forging key partnerships and securing long-term contracts with some of the largest telecommunications companies in the world, including a new project with Digicel announced earlier this year. Its solutions have been successfully deployed across 12 countries, enabling businesses to enhance their energy resilience while meeting ambitious sustainability goals.

About KULR Technology Group, Inc.
KULR Technology Group, Inc. (NYSE American: KULR) is an energy-management and reliability platform company delivering certifiable battery safety, vibration-mitigation, and thermal control solutions that enable ultra-high-power lithium-ion systems and sensitive electronics to operate reliably across space and defense missions, hyperscale AI data centers, telecom infrastructure and mobility applications.

About Caban
Caban, founded in 2018, set out to tackle the challenge of decarbonizing one of the most fossil fuel-dependent industries. Initially focused on providing alternative energy solutions for the telecommunications industry in the Americas, the company has demonstrated success in supplying energy to several of the world’s largest telecom operators. Building on this momentum, Caban has scaled globally and expanded its reach to support clean energy needs across critical infrastructure sectors worldwide. Caban uniquely combines service, hardware, software, and finance tools to deliver reliable, clean power and boosts your bottom line. This turnkey approach allows clients to work directly with one trusted partner to achieve reliability and decarbonization across their operations.

For more information, visit www.cabanenergy.com.

Find KULR: Website | X | Telegram | LinkedIn | Instagram | TikTok | Facebook

Safe Harbor Statement
This release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our Form 10-K filed with the Securities and Exchange Commission on March 31, 2025, as may be amended or supplemented by other reports we file with the Securities and Exchange Commission from time to time. Forward-looking statements include statements regarding our expectations, beliefs, intentions, or strategies regarding the future and can be identified by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” and “would” or similar words. All forecasts are provided by management in this release are based on information available at this time and management expects that internal projections and expectations may change over time. In addition, the forecasts are entirely based on management’s best estimate of our future financial performance given our current contracts, current backlog of opportunities and conversations with new and existing customers about our products and services. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise.

Investor Relations:
KULR Technology Group, Inc.
Phone: 858-866-8478 x 847
Email: ir@kulr.ai

KULR Media Relations:
M Group Strategic Communications (on behalf of KULR)
Email: kulr@mgroupsc.com

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/0b2da4ec-b5ec-46a6-8af2-19f9fac9a770


Primary Logo

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

Free Training

Source link

Samsung Biologics looks to scale up U.S. manufacturing in Maryland



Samsung Biologics CEO John Rim delivers his keynote speech outlining the company's future roadmap at the 44th J.P. Morgan Health Care Conference held at Westin St. Francis Hotel in San Francisco on Jan. 13. [SAMSUNG BIOLOGICS]

Samsung Biologics CEO John Rim delivers his keynote speech outlining the company’s future roadmap at the 44th J.P. Morgan Health Care Conference held at Westin St. Francis Hotel in San Francisco on Jan. 13. [SAMSUNG BIOLOGICS]

 
SAN FRANCISCO — Samsung Biologics is seeking to strengthen its U.S. footprint by expanding capacity at its recently acquired manufacturing facility in Rockville, Maryland, as it seeks to meet growing customer demand for U.S.-based production amid shifting trade policies.
 
“The GSK facility acquisition is anticipated to close in March this year, giving us regional presentation in the United States,” said CEO John Rim at the 44th J.P. Morgan Health Care Conference on Tuesday. “It will have flexibility to take on additional products beyond the GSK product line.”
 
Samsung Biologics announced in December 2025 that it would acquire the Rockville facility from GlaxoSmithKline for $280 million. The plant has an annual production capacity of 60,000 liters (15,850 gallons).
 
 
“It [the U.S. factory] has always been a higher cost area and everybody knows that, but for us, the U.S. was critical and the reason for that is we’ve lost customers because we didn’t have a U.S. presence,” Rim said, adding that clients wanted supply chain resiliency.
 
While the Rockville facility is modest in scale compared to Samsung Biologics’ five plants in Songdo, Korea — which together have a combined capacity of 785,000 liters — the company said the U.S. site can be expanded by an additional 20,000 to 40,000 liters.
 
“Everybody understands that there’s some pricing flexibility, so we’ll have to work through,” Rim said. “But we do see that having the Rockfield facility will open up new venues of growth for us.”
 
Initially, the plant will continue manufacturing existing GSK products, including Benlysta, a monoclonal antibody treatment for lupus. Over time, the facility is expected to be upgraded to support multiple modalities, particularly antibody production.
 
Samsung Biologics CEO John Rim delivers his keynote speech outlining the company's future roadmap at the 44th J.P. Morgan Health Care Conference held at Westin St. Francis Hotel in San Francisco on Jan. 13. [SAMSUNG BIOLOGICS]

Samsung Biologics CEO John Rim delivers his keynote speech outlining the company’s future roadmap at the 44th J.P. Morgan Health Care Conference held at Westin St. Francis Hotel in San Francisco on Jan. 13. [SAMSUNG BIOLOGICS]

 
“Whether antibody drug conjugate [ADC] capabilities are added in the future will depend on demand,” Rim added at a separate press conference held with the Korean press on Monday.
 
With the facility, the Korean company will have more than 500 employees working at the site, and plans to recruit more U.S talent in the future.
 
The company’s main production site, however, remains rooted in its Songdo campus as U.S. tariffs on biopharmaceutical imports have largely dissolved. While tariffs were previously discussed at levels as high as 250 percent, subsequent bilateral negotiations have capped potential tariffs at 15 percent, significantly reducing trade-related risk.
 
In parallel, Samsung Biologics is continuing to expand domestically. Construction of a sixth plant is expected to begin between 2026 and 2027, and the company has secured land for a third phase of its Songdo manufacturing campus. It plans to invest approximately 7 trillion won ($4.7 billion) through 2034 to build additional production facilities.
 
Looking ahead, Rim said the company’s investment strategy, including mergers and acquisitions, will remain focused on antibody manufacturing.
 
 
The global biopharmaceutical market is projected to grow at a compound annual growth rate of 10 percent, from $565 billion in 2025 to $921 billion in 2030, according to market researcher Evaluate Pharma, driven in particular by monoclonal antibodies, multispecific antibodies, ADCs and fusion proteins.
 
“The antibody market is so large that even single-digit growth translates into meaningful demand,” Rim said. “Other segments may grow faster in percentage terms, but their overall impact is limited by smaller market size.”
 
Samsung Biologics is also closely monitoring developments in GLP-1 therapies — particularly the shift toward oral formulations — as well as opportunities in peptide manufacturing.
 
The company has rebranded its contract manufacturing offering under the name ExcellenS, a move that reflects its emphasis on tailored production and operational efficiency, based on standardized and scalable manufacturing processes.
 
Samsung Biologics is scheduled to report its fourth-quarter and full-year 2025 earnings on Jan. 21. The company recorded a record annual order intake of 6.8 trillion won in 2025, with cumulative orders surpassing $21 billion.
 

BY LEE JAE-LIM [[email protected]]

Free Training

Source link

Could Gulf States Pivot to Silicon Manufacturing for AI?


Infrastructure requirements

Pax Silica centres on resolving three essential vulnerabilities in the technology manufacturing supply chain.

The initiative addresses critical minerals processing, with China controlling approximately 90% of global rare earth processing capacity.

The pact seeks to establish an alternative, Western-aligned supply chain for materials required for advanced chip manufacturing facilities.

This agreement focuses on manufacturing infrastructure and power supply requirements.

AI data centres and semiconductor fabrication plants require substantial energy resources, with consumption projected to triple by 2030.

Both the UAE and Qatar possess significant electricity generation capacity, which could support the large-scale manufacturing facilities and “compute farms” needed to develop next-generation AI models and process the chips that power them.

The agreement involves considerable capital deployment into manufacturing projects.

The Qatar Investment Authority oversees assets worth approximately US$524bn, while UAE sovereign funds manage more than US$1tn.

These financial vehicles are already being channelled into ventures such as “Stargate,” the US$500bn data centre project involving OpenAI and SoftBank, alongside a US$100bn collaboration between Abu Dhabi’s MGX, BlackRock and Microsoft focused on AI infrastructure manufacturing.

Free Training

Source link

Why US-Based Manufacturing Is Becoming a Strategic Imperative for Biopharma


According to Franco Stevanato, CEO of Stevanato Group, tariff policies are beginning to influence how pharmaceutical companies think about manufacturing location and supply chain resilience, but the shift toward localization will take time. While tariffs have created temporary cost pressures for the company, including surcharges passed on to customers, those impacts have largely been accepted by clients and are not yet driving immediate supply chain reconfiguration.

Stevanato operates 13 sites across nine countries and generally supplies products regionally, though certain items continue to be manufactured in Europe. Capacity expansion in the US—particularly at the company’s facility in Fishers, IN—is underway, but meaningful ramp-up will take several more years. In the short term, the company cannot quickly redirect production or fully restructure its global supply network.

Despite these near-term headwinds, Stevanato sees tariffs as a catalyst for longer-term opportunity. The company already has significant campus infrastructure in place, positioning it to benefit as customers reassess their footprint strategies. Over a three- to four-year horizon, leadership expects more pharmaceutical manufacturers to increase investment in US-based production as they seek to mitigate trade risks, improve regional supply continuity, and align manufacturing closer to end markets.

However, the pace of change is constrained by the realities of pharmaceutical operations. Site development, validation, regulatory approvals, and capacity scaling require long lead times, making rapid shifts impractical. Decisions around localization must also align with pharma companies’ internal investment cycles and long-term network planning.

Overall, tariffs are not triggering immediate supply chain realignment, but they are accelerating strategic discussions around regionalization and domestic capacity. For packaging companies like Stevanato, this evolving landscape presents a medium-term growth opportunity as customers gradually move toward more localized and resilient manufacturing models—particularly in North America—while managing short-term operational and cost pressures.

Stevanato also discussed the strategic advantages to expanding production within the US and much more.

A transcript of his conversation with PC can be found below.

PC: Beyond tariff mitigation, what strategic advantages does expanding production within the US offer for biopharma clients?

Stevanato: Beside the tariff, the pharma companies want to always have a strategic partner, because we say that we sell critical containment solution, because our product is entering contact with the drugs. So this is going to require to have validation filings with the FDA. The stability of the drugs is a very complex, expensive process—because we are filing with the FDA, the pharma customer automatically wants to secure the supply chain. They want always at least two sites.

Now, they want two sides for certain critical molecules, particularly for certain blockbusters that are also in two different regions. This is why, already in 2021, we decided to build these Greenfield plants. Now, the fact that we have this big campus in the United States with the possibility to accelerate will make Stevanato even more attractive compared to certain competitors, to sign future additional potential contracts.

This is what we see, starting from many clients. They are changing their supply chain. They are reshoring a little bit—for some biosimilars, they usually they use a supplier in the Far East. They’re starting to build the supply chain in United States. These are all positive signals that will help enhance Stevanato eventually further boost our business plan in the medium term.

Free Training

Source link